Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting
timothy sykes logo

Stock News

Black Diamond Stock Jumps: Right Time to Buy?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 3/20/2025, 5:04 pm ET 6 min read
Black Diamond Stock Jumps: Right Time to Buy? Thumbnail

Black Diamond Therapeutics Inc.’s recent fruitful collaboration with a major pharmaceutical company is expected to drive substantial market interest. On Thursday, Black Diamond Therapeutics Inc.’s stocks have been trading up by 5.91 percent.

Global Licensing Agreement with Servier:

  • Black Diamond has inked a strategic global licensing deal with Servier to develop and commercialize a promising new therapy, BDTX-4933, for solid tumors, gaining a sizable upfront payment of $70M along with potential milestone rewards reaching up to $710M. This deal provides Black Diamond with great resources for future innovations.

Candlestick Chart

Live Update At 17:04:17 EST: On Thursday, March 20, 2025 Black Diamond Therapeutics Inc. stock [NASDAQ: BDTX] is trending up by 5.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Just as Black Diamond and Servier finalized their global agreement, the company’s shares boomed, logging an impressive 9% increase. Prospective investors are questioning whether this rise signifies a savvy moment to buy BDTX stock before it potentially surges further.

  • The agreement bolsters Black Diamond Therapeutics’ reputation in targeted cancer treatments, marked by a prior price elevation of their stock ventures. This likely fuels more strong investor interest and signifies possible continued momentum in BDTX’s market performance.

  • Stifel retained a Buy stance on Black Diamond shares, albeit adjusting the price target from a hefty $16 to $15. The modest drop showcases an inclination towards caution, but faith in long-term growth remains. Could this be just a hiccup? Many are inclined to think so.

  • While Wedbush lowered Black Diamond’s price expectation to $11 from $16, they continued to support the prospect of an outperforming streak for BDTX, weighing more on potential upcoming triumphs lying ahead in their product evolution.

Analyzing Recent Earnings and Financial Health:

Looking at Black Diamond’s earnings, their latest report revealed some interesting points. At the year’s close, they disclosed a holding in cash of about $98.6M while championing their progress geared towards treating non-small cell lung cancer with their candidate, BDTX-1535. The revenue observed for the period amounted to a rather modest $992,000. However, the consolidated net losses stood out significantly at $15.985M. Yet, the comprised R&D expenses, approximately 12.297M in dollars, signify ongoing efforts that echo the sentiment of strategic resilience in the trading world. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Black Diamond seems committed to this trading principle, ensuring that each decision secures their foothold while forging ahead into new treatment avenues.

Key ratios paint a picture with stark contrasts: Black Diamond’s gross margin stands vibrant at 307.7%, yet profitability outlines remain steeply negative. An ebit margin figures at around -7,023.8%, marking heavy investments without immediate returns across their pipeline innovations. Balance commitments reveal long-term debt totals at $18.782M, indicating manageable obligations amidst growing revenue expectations.

More Breaking News

Asset evaluations, like Black Diamond hold no current leverage issues, with equity surpassing liabilities comfortably. Judicious reserve management, evident in quick ratio sitting at 4.8 and current as well at a ratio of 4.9, coupled with consistent cash-flow maneuvering, speaks well for anticipated product development accomplishments.

Impact of Recent Collaborations on Stock Value:

Many investors look at BDTX’s collaboration with Servier as a nod to Black Diamond’s resilient market strategy. Besides attracting a rewarding monetary deal, the agreement strengthens Black Diamond’s therapeutic reach. By increasing confidence in their innovation pipeline, it opens potentially lucrative doors in clinical spaces for solid tumor treatment, charting paths to further market captures.

The surge observed following this deal undeniably piques investor interest. With certainty, a strengthened cash infusion directly endorses continued explorations in their portfolio, alongside attracting institutions and private players ready to witness therapy milestones over the horizon. Moreover, the contained volatility surrounding the stock post-announcement underpins confidence alone further builds investor trust, solidifying potential long-term growth.

Concluding Thoughts and Market Outlook:

News surrounding Black Diamond’s current endeavors suggests stock enthusiasts must look closely at recent undertakings in strategic placements. An empowered influx of funds via their Servier deal furthers product discoveries, serving as catalysts for core therapeutic advancements.

Conclusively, Black Diamond demonstrates calibrated focus within oncology spheres. This enables projections inferring emergent market positioning extending beyond conventional expectations. The bouncing stock price aptly mirrors this phase of evolution, driven by targeted collaborations and determined strides in cancer therapies. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” For those observing the market, it’s crucial to maintain discipline and not rush decisions based merely on fear of missing out.

Overall, Black Diamond Therapeutics Inc. adheres to a calculated path, propelled by key agreements, poised on paving meaningful shares in the oncology domain. Traders tuned to the development automotive aspect might just anticipate immense returns — if and when profound clinical success stories, steeped in growth narratives, transform into quantifiable achievements.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications